BioMarin Pharmaceutical Inc. v. Ascendis Pharma, Inc. et al.
settled/dismissed- Docket:
- 337-TA-1447
- Filed:
- 2025-04-02
π BioMarin Pharmaceutical Inc.Δ Ascendis Pharma, Inc.Δ Ascendis Pharma A/SΔ Ascendis Pharma Growth Disorders A/SΔ Wacker Biotech GmbHΔ Bachem AG
ITC Section 337 investigation titled Certain Drug Products Containing C-Type Natriuretic Peptide Variants, and Components Thereof, brought by BioMarin against Ascendis entities and suppliers regarding TransCon CNP / navepegritide. The asserted patent was U.S. Reissue Patent No. RE48,267; US 8,377,884 was relied on by Ascendis as prior-art Exhibit 32, not asserted. Resolved by a global settlement announced August 30–31, 2026, with the investigation to be dismissed.